Previous 10 | Next 10 |
2024-06-13 09:49:40 ET More on JPMorgan Chase JPMorgan Chase & Co. (JPM) Morgan Stanley US Financials, Payments & CRE Conference JPMorgan Chase: Just By Opening 500 New Branches, It Could Potentially Generate Another $9.11B In Revenues JPMorgan Chase hires fo...
2024-06-13 07:18:52 ET Summary The Schwab U.S. Large-Cap Growth ETF is an excellent alternative to the Invesco QQQ Trust. Its holdings overlap the QQQ's to a considerable degree, but with a much lower fee, and exposure to financials. This makes sense because the Dow Jones Larg...
2024-06-13 02:30:42 ET Summary A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-ye...
2024-06-12 18:34:33 ET Summary At today's FOMC meeting, the Fed held interest rates steady and signaled that it's likely to cut less than the market thinks. This is somewhat surprising given that the econometric models I run are suggesting that the Fed has room to cut. Between...
2024-06-12 14:39:17 ET More on Eli Lilly Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? GLP-1 obesity drug...
2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...
2024-06-12 10:27:30 ET More on Palatin Tech Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript Palatin Tech GAAP EPS of -$0.53 misses by $0.03 Palatin Tech Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on Palatin Tech His...
2024-06-12 10:16:29 ET Summary Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. ...
2024-06-11 14:24:55 ET Summary Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab, the second FDA-approved Alzheimer's treatment on the market. It is too soon to know what kind of impact Lilly’s Donanemab will have on future ear...
2024-06-11 14:00:18 ET Summary Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for Alzheimer's treatment, but concerns remain post-approva...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...